VJHemOnc is committed to improving our service to you

ASH 2019 | Outcomes of CPX-352 vs. 7+3 for t-AML

VJHemOnc is committed to improving our service to you

Jeffrey Lancet

Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, discusses the exploratory analysis of a phase 3 study performed to compare outcomes in patients with therapy-related acute myeloid leukemia (t-AML) who achieved remission with CPX-351 (daunorubicin and cytarabine in a liposomal formulation for injection) vs 7+3 chemotherapy (NCT01696084). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter